| Summary: | Doxorubicin is chemotherapy agent which is commonly used for breast cancer therapy. Doxorubicin can give side effect like suppress immune system. To reduce its effect, we can use co-chemotherapy agent. Polysaccharide fraction of mengkudu (Morinda citrifolia L.) has been reported to have anticancer effect and immunostimulant. The aim of this research is to evaluate the effect of polysaccharide fraction of mengkudu on Vero and T47D cells proliferation after treated by doxorubicin.
Polysaccharide fraction of mengkudu was tested on Vero and T47D cells as co-chemotherapy agent of doxorubicin by in vitro assay. Vero and T47D cells were treated using doxorubicin in concentration 40,95 μM and four concentrations of polysaccharide. Cell proliferation were determined using MTT-reduction assay, and its absorbance was measured at 550 nm. The data was analyzed using SPSS 19 program.
Based on this result, combination of doxorubicin (40,95 μM) and 25 μg/mL of polysaccharide is not significantly decrease Vero cells viability. Combination of doxorubicin (40,95 μM) and 25, 50, 100 and 200 μg/mL of polysaccharide is not significantly decrease T47D cells viability. Based on PSA analysis, polysaccharide fraction of mengkudu contain 43,06 ± 1,72% b/b total polysaccharide dextran equivalent.
Keywords: polysaccharide, mengkudu, Vero cells, T47D cells
|
|---|